1-3 of 3
Alison Vellani
Close
Sort by
Journal Articles

A Phase II Trial of Combination Therapy with Thalidomide, Arsenic Trioxide, Dexamethasone, and Ascorbic Acid (TADA) in Patients with Overlap Myelodysplastic/Myeloproliferative Diseases (MDS/MPD) or Chronic Idiopathic Myelofibrosis (CIMF).

Mikkael A. Sekeres, MD, MS, Jaroslaw P. Maciejewski, MD, PhD, Matt Kalaycio, MD, Mary Laughlin, MD, PhD, Ronald Sobecks, MD, Anjali Advani, MD, Katarina Paulic, Josephine Chan, Alison Vellani, Azra Raza, MD
Journal: Blood
Blood (2007) 110 (11): 1457.
https://doi.org/10.1182/blood.V110.11.1457.1457
Published: 2007
Journal Articles

Comparing Psychosocial Profiles and Outcomes between Patients Undergoing Myeloablative and Non-Myeloablative Allogeneic Transplants.

Linda McLellan, Larry W. Foster, Lisa Rybicki, Jane Dabney, Michele Visnosky, Sungren Sungren, Alison Vellani, Nicole Berry, Kelly Cherni, Laura Bernhard, Jennifer Kosar, Mary Serafin, Karen Sands, Christina Ferraro, Brian J. Bolwell
Journal: Blood
Blood (2006) 108 (11): 77.
https://doi.org/10.1182/blood.V108.11.77.77
Published: 2006
Journal Articles

The Kinetics of Etoposide (VP-16) Peripheral Blood Progenitor Cell (PBPC) Mobilization.

Brian J. Bolwell, M.D., Elizabeth Kuczkowski, Lisa Rybicki, Brad Pohlman, M.D., Steven Andresen, D.O., Ronald Sobecks, M.D., Janet Baker, R.N., Kelly Cherni, R.N., Laura Bernhard, R.N., Alison Vellani, Nicole Berry, Shawnda Sungren, Leslie Foster, Matt Kalaycio, M.D.
Journal: Blood
Blood (2004) 104 (11): 4993.
https://doi.org/10.1182/blood.V104.11.4993.4993
Published: 2004